A human hematopoietic disorder designated as Tn syndrome or permanent mixed-field polyagglutinability has been ascribed to a stem cell mutation leading to a specific deficiency of UDP-Gal:GalNAcal-O-Ser/Thr #1-3 galactosyltransferase (#3Gal-T) activity in affected cells. To test for the possibility that an allele of the ,3Gal-T gene might be repressed instead of mutated, we have investigated whether 5-azacytidine or sodium n-butyrate, both inducers of gene expression, would reactivate expression of #3Gal-T in cloned enzyme-deficient T cells derived from a patient affected by the Tn syndrome. Flow cytometry revealed that a single treatment induced de novo expression of the Thomsen-Friedenreich antigen (Gal,61-3GalNAc-R), the product of 63Gal-T activity. In addition, a sialylated epitope on CD43 (leukosialin), which is present on normal but not on ,3Gal-T-deficient T cells, was also reexpressed. Although no #3Gal-T activity was detectable in untreated Tn syndrome T cells, after exposure to 5-azaC, #3Gal-T activity reached nearly normal values. Both agents failed to reactivate ,63Gal-T in Jurkat T leukemic cells, which also lack #3Gal-T activity. These data demonstrate that Tn syndrome T cells contain an intact B83Gal-T gene copy and that the enzyme deficiency in this patient is due to a persistent and complete but reversible repression of a functional allele. In contrast, the cause of 03Gal-T deficiency appears to be different in Jurkat T cells. (J. Clin.
Introduction
Tn syndrome or permanent mixed-field polyagglutinability (PMFP)' is a human disorder characterized by the exposure of truncated 0-glycans, in particular the Tn antigen (GalNAca 1-O-Ser/Thr) (1) due to a selective deficiency of UDP-Gal:GalNAca l-O-Ser/Thr #1-3 galactosyltransferase (f3Gal-T) activ-ity (2, 3) in a variable proportion of hematopoietic cells (4) . These patients, who are also said to have blood group Tn (5), occasionally develop hemolytic anemia, thrombopenia, and leukopenia most likely mediated by anti-Tn natural antibodies present in normal serum (6) . Tn polyagglutinability has been observed in the context of hemoproliferative disorders (7) and Tn antigen expression may also accompany malignant transformation (8) . The enzyme deficiency was thought to arise from a somatic stem cell mutation resulting in the clonal penetration ofTn antigen-expressing cells into the various hematopoietic lineages (9) . Thus, Tn antigen-expressing cells circulating in peripheral blood of PMFP patients have been considered glycosylation variants carrying a somatic mutation that has irreversibly destroyed f33Gal-T activity.
In principle, absence of a functional gene product may be due to either mutation or repression. In the context of blood group biosynthesis, an example of a mutated gene is observed in the histoblood group ABO system (10) . A single-base deletion in the 0 allele causing a frame-shift leads to expression ofa nonfunctional protein, whereas in case of A or B genotypes, functionally active glycosyltransferases are produced. On the other hand, stable gene repression with mutation-like characteristics is well known to occur in transformed permanent cell lines ( 11) . This appears to be, however, a phenomenon induced in vitro by cell culture conditions selecting for rapid growth, which lead to the silencing of nonessential genes. The loss of specific functions was originally ascribed to structural gene mutations and the new isolates were designated as mutants. However, many ofthese "mutants" could be reverted by treatment with 5-azacytidine (5-azaC), a potent inhibitor of DNA methylation ( 12, 13) . DNA methylation is also thought to play a role in gene regulation during blood cell differentiation. The IL-3-dependent multipotential stem cell clone LyD9 could be induced to differentiate into neutrophils and macrophages without direct contact with stromal cells by pretreatment with 5-azaC ( 14) . Furthermore, 5-azaC reactivates expression of CD4 on CD8+ peripheral blood T cells ( 15 ) , suggesting that DNA hypermethylation also correlates with persistent repression of gene activity during maturation of human T cells. This observation is substantiated by the fact that acquisition of glucocorticoid resistance of human T cells is accompanied by de novo DNA methylation and sensitivity may be recovered after treatment with 5-azaC ( 16) . In addition, 5-azaC has been used to induce constitutive IL-2 production in EL-4 thymoma cells ( 17) .
Other agents that are known to induce different expression of phenotypic and functional properties include sodium n-butyrate (NaB) and DMSO, well known for their differentiationinducing effect on human promyelocytic HL-60 cells and murine erythroleukemia cells (18) (19) (20) . While gene expression could also be induced in T lymphoid cells by NaB, as demonstrated by the finding that latent HIV-1 could be reactivated in chronically infected cells (21 ), DMSO appeared to be less ef-fective as an inducer of gene expression in B and T lymphoid cells (22) . Thus, 5-azaC and NaB should be useful agents to activate possibly intact but silent genes in human T cells.
In PMFP patients, Tn+ cells deficient in ,33Gal-T activity and TF+ cells containing enzyme activity levels comparable with cells from control subjects coexist in peripheral blood. This "mosaic status" in PMFP peripheral blood strongly suggested that Tn expression arises from a somatic mutation in a pluripotent stem cell followed by clonal expansion into the various lineages (5) . To test the alternative possibility that PMFP represents an example of a disorder caused by repression of an otherwise intact f3Gal-T gene, we have investigated T cells deficient in j33Gal-T activity. For this purpose, we took advantage from Tn+ T cell clones recently established in our laboratory from the PBL of a well-characterized patient (R.R.) (4) . These Tn+ T cells represented nontransformed cells reflecting an in vivo situation and thus provided a system to investigate whether repression of a functional allele of the f3Gal-T gene may be responsible for the enzyme deficiency.
Here we report that PMFP T cells reexpress 33Gal-T activity after exposure to 5-azaC or NaB, resulting in surface expression of the TF antigen (Gal# I -3GalNAc-R). Moreover, 5-azaC induces reconstitution ofa sialylated epitope on CD43 (leukosialin), which is present on normal but not on PMFP T cells. Our data indicate that galactosyltransferase deficiency in PMFP arises from the silencing of an intact 33Gal-T allele. In contrast, 5-azaC and NaB did not reactivate g3Gal-T in transformed T cells (Jurkat).
Methods
Antibodies. TKH6 (IgM anti-Tn) and HH8 (IgM anti-TF) mAb were described previously (4, 23) . DF-Tl, the sialic acid (NeuAc)-dependent mAb anti-CD43 (IgG 1) (24) was purchased from Dakopatts (Copenhagen, Denmark). The epitope recognized by DF-Tl was designated CD43NUAC in this work. Binding of mAb was revealed by fluoresceinated goat anti-mouse Ig (Southern Biotechnology Associates, Birmingham, AL).
Culture media. The culture medium IMDM (Gibco Laboratories, Grand Island, NY) was supplemented with L-glutamine (300 ,ug/ml)), 1% (vol/ vol) ofa I O0X mixture ofnonessential aminoacids, 100 U/ ml penicillin, 100 ,g/ml streptomycin, and 10% (vol/vol) heat-inactivated fetal calf serum (IMDM-FCS) or 5% (vol/vol) pooled human A serum (IMDM-HS). To support growth of T cell clones, IMDM-HS was supplemented with 100 U/ml recombinant human IL-2 (generously supplied by Dr. F. Sinigaglia, Hoffmann-La Roche, Basel, Switzerland). T cell lines and culture. The generation and characterization of the CD4+ PMFP T cell clone used in this study has been described recently (4) . Briefly, the Tn+ subpopulation ofthe PBL from patient R.R. was enriched by a negative sorting on a fluorescence activated cell sorter. T (4) . Protein concentrations of cell lysates were determined with the bicinchoninic acid protein assay reagent (Pierce Chemical Co., Rockford, IL) and BSA as a standard according to the manufacturer's instruction. Protein concentrations were adjusted to 1 mg/ml. To all assays 50 Al of T cell lysate was added as a source for f3Gal-T activity. Extracts were also prepared from control cultures consisting of APC alone.
Specific assay for f3Gal-T enzyme activity. f3Gal-T activity in T cell lysates was assessed using asialo-ovine submaxillary mucin (OSM) as exogenous acceptor substrate as described by Berger et al. (27) . Controls included reactions in the absence of exogenous acceptor substrate and full reaction mixtures stopped immediately (zero time). No difference was observed between these two controls. Control values were subtracted from values obtained after 30 and 60 min of incubation in the presence of added acceptor. Background activity contained in remaining APC was also determined and subtracted in each case. All measurements were carried out in duplicates.
The reaction mixture contained in a final volume of 100 Al, 50 tor was precipitated by the addition of 0.9 ml of ice-cold 5% (wt/vol) phosphotungstic acid in 2 M HC1. The precipitate was filtered over glass fiber filters (GF/ A; Whatman Inc., Clifton, NJ) and washed with excess phosphotungstic acid and ethanol (-20'C) to remove the unreacted UDP-[ 14C ]Gal. Filters were dried under vacuum and radioactivity was determined in a liquid-scintillation counter using 4 ml of Toluol-Butyl-PBD (Ciba Geigy, Summit, NJ) as scintillation fluid.
Results
Tn antigen-positive Tcellsfrom a PMFP patient lack ,33Gal-T activity. Tn+ T cells deficient in 33Gal-T activity were cloned from the PBL of patient R.R. as described previously (4).
These cloned lines were continuously expanded for > 1 yr without alterations of the Tn phenotype. A clone belonging to the CD4+ subset was used to test for reexpression of O-glycosidic antigens. For this purpose, treated cells were probed by two mAbs as follows: in a first series we used HH8, which is directed to the TF antigen (Gal: 1-3GalNAc-R) (Fig. 1) , the product of 33Gal-T activity. Since the TF antigen is sialylated after its Fig. 3 0) , which are incompletely sialylated as a consequence of defective 0-galactosylation (4).
It was thus reasonable to assume that reactivation of 03Gal-T activity should result in synthesis of the TF antigen and its subsequent sialylation in the reconstitution of the DF-T 1 epitope. In addition to HH8 and DF-T 1, we show data obtained with mAb TKH6 directed to the Tn antigen (GalNAcal-0-Ser/Thr) (Fig. 1) . As previously shown, TKH6 binds to PMFP but not to normal T cells (4 Fig. 3 . The Tn antigen is expressed on PMFP (Fig. 3, C and D) but not on normal donor T cells (Fig. 3, A and B) . Indeed, after exposure to 5-azaC, a subpopulation of the treated PMFP cells failed to bind TKH6 (Fig. 3 E) . We believe that these cells are not actually Tn-in the sense of lacking GalNAc residues. It seems more likely that they express a modified Tn antigen such as the TF antigen or the sialosyl-Tn antigen (Fig. 1 ), since pretreatment with neuraminidase partly unmasked Tn antigen detectable by TKH6 (Fig. 3 F) . The TF antigen can be detected on normal desialylated T cells (Fig. 3 H) . In contrast, PMFP cells completely lack TF antigen (Fig. 3 J) as previously described (4) . Indeed, treatment of PMFP T cells with 5-azaC induced expression of TF antigen on a sizeable subset (Fig. 3 L) , suggesting reactivation of 33Gal-T. Moreover, as inferred from fluorescence intensity, TF antigen synthesis induced by 5-azaC appeared to reach a level comparable to normal donor T cells (Fig. 3, compare L with H) . However, pretreatment with neuraminidase was necessary to detect TF antigen (Fig. 3 , compare K with L), indicating subsequent and complete sialylation of the newly synthesized TF antigen. DF-Tl strongly labels normal donor T cells (Fig. 3 M) . Binding of DF-T1 is completely abolished by enzymatic desialylation (Fig. 3 N) . The sialic acid (NeuAc)-containing epitope is not expressed on PMFP T cells (Fig. 3 0) , which lack O-linked sialic acid because ofdefective O-galactosylation (4). Again, after 5-azaC treatment the DF-T1 epitope was expressed on a large subset ofthe treated PMFP cells (Fig. 3 Q) . As in the case of control cells (Fig. 3 N) , the DF-T 1 epitope expressed de novo on PMFP T cells proved to be sensitive to neuraminidase treatment (Fig. 3 R) .
Induction of0-glycosidic antigens by NaB. To answer the question whether reexpression of TF antigen and the CD43NCUAC epitope is specifically due to the mechanism of action of 5-azaC, similar experiments were carried out with NaB. (Fig. 4 B) . Table I summarizes the respective percentages and MFIs of representative induction experiments using 5-azaC and NaB. Flow cytometry results obtained after NaB treatment were qualitatively similar to those depicted in Fig. 3 . A rather nonspecific inducing agent is DMSO, which causes differentiation of HL-60 and murine erythroleukemia cells ( 18, 20) . In contrast to 5-azaC and NaB, treatment with 1 D) were isolated by FACS using DF-T1, reanalyzed subsequent to sorting (G) or periodically restimulated (2-wk intervals) and reanalyzed with DF-T1 (H and I) or HH8 (J and K). In addition, the respective percentages were also determined in the mixed population that had not been subjected to cell sorting (B, C, E, and F). Fig. 5 , A-F, antigenpositive cells were clearly detectable at 4 (Fig. 5, B and E) and 6 wk (Fig. 5, C and F) after treatment. However, we observed that the percentage of antigen-positive cells decreased. To answer the question whether this was due to reversion to the original phenotype or to a growth disadvantage of the 5-azaC responding cells, treated cells were labeled with DF-T1 2 wk after treatment and fluorescence-positive cells were isolated using a FACS (Fig. 5 G) followed by periodic restimulations. Analysis at 2 (Fig. 5 H) and 4 wk (Fig. 5 I) after sorting (4 and 6 wk after 5-azaC treatment, respectively) revealed again that the cell population that bound DF-T1 decreased. Moreover, the staining patterns (Fig. 5 , Hand I) suggested that, indeed, reversion back to the Tn phenotype contributes to the observed phenomenon. This observation suggests that the f33Gal-T allele is only transiently derepressed in the treated cells. In addition, those cells that were enriched using DF-Tl also bound HH8 (Fig. 5 Incubation time (min) Figure 6 . Reactivation of ,B3Gal-T activity in PMFP T cells. ,B3Gal-T activity was determined in T cell lysates using asialo-OSM as acceptor substrate as described in Methods. gens detected on the cell surface to the induction of f33Gal-T activity, cellular enzyme activity was determined. Detergent cell lysates from 5-azaC-treated PMFP T cells and untreated control cells were assayed using asialo-OSM as acceptor substrate (2, 4, 27) . As depicted in Fig. 6 , no activity could be detected in untreated PMFP T cells which is in accordance with the lack ofdetectable TF epitopes (Fig. 3 J) . On the other hand, pretreatment of PMFP cells with 5-azaC resulted in a significant increase of ,3Gal-T activity in the total lysate ofthe treated cells ( -30 pmol mg-1 min-'). As shown by flow cytometry, activation of ,B3Gal-T resulted in efficient TF antigen synthesis in 25% of the cells, indicating that in individual cells responding to 5-azaC f33Gal-T activity was indeed comparable to the activity present in normal donor T cells (160 pmol * mg-' -min-'). These data clearly demonstrated reactivation of f3Gal-T in PMFP T cells.
Failure of5-azaC and NaB to reactivate f3Gal-T in Jurkat T cells. The T lymphoblastoid leukemia cell line Jurkat also expresses the Tn antigen because of 33Gal-T deficiency (31 ) . It is unclear whether Jurkat T cells represent transformed PMFP cells or originate from normal T cells that have lost gene activity during malignant transformation. Treatment of a Jurkat cell clone completely deficient in TF antigen synthesis (4) with 5-azaC or NaB as described in Methods, however, did not induce de novo expression of O-glycosidic antigens, suggesting that the gene encoding f33Gal-T is either irreversibly repressed or mutated.
Discussion
More than a decade ago, deficiency of 33Gal-T activity was shown to be the underlying enzymatic defect causing PMFP (2, 3) . A somatic mutation occurring at the stem cell level was suggested to be responsible for the loss of gene activity ( 1, 9) but thus far, the molecular nature of,3Gal-T deficiency has not been analyzed due to a major experimental limitation: the enzyme deficiency was first reported to occur in erythrocytes (2) and thrombocytes (3). However, both represent only fragmented cells, which cannot be stimulated to undergo cell division. Gahmberg and colleagues (32) established a polyclonal B lymphoblastoid cell line with the Tn phenotype by EBV transformation but they did not report studies on the molecular mechanism causing 03Gal-T deficiency. We have recently established T cell clones with the intrinsic defect from the PBL of a well-characterized patient (4) . These T cell clones reflect an in vivo condition and thus provided the basis for investigations of the molecular nature of the PMFP defect.
In the present report, we have examined the possibility that (14, 33, 34) and to induce cellular genes ( 12, (15) (16) (17) and viruses (35) Indeed, exposure of PMFP T cells to 5-azaC results in induction of f3Gal-T activity (Fig. 6) . Furthermore, reactivation of f3Gal-T activity induced by 5-azaC and NaB, respectively, could also be monitored by the reappearance of the TF antigen on the cell surface using a TF antigen-specific mAb capable of labeling lymphocytes (4) and flow cytometry (Fig.  3) . In addition to the TF antigen, a sialylated epitope on CD43, which characterizes normal T cells, was expressed de novo on PMFP T cells after treatment with 5-azaC or NaB. The molecular nature of some of the investigated epitopes need further analysis. We observed that the percentage of cells binding DF-T 1 was always higher than the percentage ofHH8 binding cells, suggesting that de novo synthesis of the sialosyl-Tn antigen (Fig. 1 ) may be sufficient for binding of DF-T 1. This hypothesis is supported by the fact that flow cytometry revealed a population unreactive with TKH6 after 5-azaC treatment (Fig. 3  E) . However, the Tn antigen was unmasked on some of these cells after treatment with neuraminidase (Fig. 3 F) . This subpopulation thus expresses the sialosyl-Tn antigen and may also bind the sialic acid-dependent DF-T l. An additional explanation would be that 31-6 N-acetylglucosaminyltransferase normally induced during T cell activation (37) could be coinduced after exposure to 5-azaC. The tetrasaccharide (Fig. 1 , structure IV) expressed on normal resting T cells would then be converted to the hexasaccharide NeuAca2-3GalfB1-3(NeuAca2-3Gal3 l-4GlcNAc3 1-6 )GalNAc-R (Fig. 1, structure V) . This further substitution of the TF antigen would definitely prevent binding of HH8 (4) (4, 31) . Possibly, Jurkat T cells synthesize sialosyl-Tn antigens, which is supported by the observation that neuraminidase treatment enhances binding of TKH6 (not shown), or GlcNAc-containing derivatives ofthe Tn antigen with terminal sialic acid (37) , providing epitopes for DF-T 1. Thus, the phenotypes of PMFP and Jurkat T cells concerning 0-glycosylation are similar but not identical.
Development of the Tn phenotype may be the result of the repression of both 33Gal-T gene copies, an event that may be accompanied by DNA methylation. An alternative possibility is that just one ofthe two alleles becomes repressed, resulting in functional hemizygosity (38) . Subsequently, mutagenesis of the active allele would then lead to enzyme deficiency, and 5-azaC or NaB will reactivate the silent nonmutant allele (39) . However, the 33Gal-T protein has not been purified to homogeneity nor has its cDNA been cloned. Thus, the molecular genetic analysis necessary to determine the actual mechanism(s) inducing f,3Gal-T deficiency must await the availability of molecular probes.
We have also to keep in mind that not necessarily the ,B3Gal-T gene itself needs to be inactivated. A cellular transcription factor essential for expression of f33Gal-T might as well be the target of the inactivation event leading to l33Gal-T deficiency. The question, however, remains what induces 33Gal-T gene repression. A possibility to be further investigated could be viral inactivation as suggested by the finding that viruses integrated in the host cell genome are suppressed by mechanisms including DNA methylation (39) and latent viruses can be induced by 5-azaC (35) and NaB (21 ). Moreover, in Mov substrains of mice, insertion of a retrovirus induced de novo methylation of host DNA sequences and this change of the DNA methylation pattern correlated with the inactivity of a collagen gene (40) .
fl3Gal-T deficiency is also observed in transformed T cells (Jurkat) (31 ) and in the majority of carcinomas that thereby accumulate the Tn antigen or synthesize the sialosyl-Tn antigen (8) . It will be interesting to test whether carcinoma cells recover enzyme activity after treatment with agents such as 5-azaC, NaB, or other agents that interfere with gene expression. However, in our study 5-azaC and NaB failed to induce 33Gal-T enzyme activity in Jurkat T cells, suggesting that the mechanism of inactivation is different in these cells. Nevertheless, the possibility that Jurkat cells contain an intact fl3Gal-T gene that is not inducible due to a more tight repression cannot be excluded. In addition, loss ofgene expression in cancer cells of hematopoietic origin could also be due to gene translocations occurring during oncogenic transformation (41) . Taken together, the 33Gal-T locus appears to be very susceptible to gene inactivation events. In summary, we present evidence that Tn+ T cells from PMFP patient R.R. contain at least one intact 33Gal-T allele, which is, however, persistently and strongly suppressed by a mechanism involving DNA methylation and histone deacetylation. We thus suggest that in stem cells or early hematopoietic progenitor cells of PMFP patients the f3Gal-T site becomes inhibited during a "critical event," resulting in clonal inheritance of the repression into the various lineages.
